MART-1(24-33(34))

MART-1(24-33(34)), also known as Melanoma Antigen Recognized by T cells 1 (residues 24 to 33 or 34), is a synthetic peptide fragment derived from the MART-1 protein, a melanocyte differentiation antigen. This peptide sequence is widely recognized for its immunological significance, particularly in the context of melanoma research, as it encompasses a key epitope targeted by cytotoxic T lymphocytes (CTLs). The fragment's defined amino acid sequence and immunogenic properties make it a valuable reagent for studies focused on antigen processing, T cell recognition, and the broader mechanisms of tumor immunology. Its use extends across multiple experimental platforms, supporting both basic and translational research in cellular immunology and peptide-based assay development.

Epitope Mapping: As a well-characterized T cell epitope, the MART-1(24-33(34)) peptide is extensively employed in epitope mapping studies. Researchers utilize this peptide to delineate the specific regions of the MART-1 protein that are recognized by CTLs, enabling a detailed understanding of immune specificity. Such mapping is crucial for dissecting the molecular interactions underpinning T cell receptor (TCR) engagement and for identifying immunodominant sequences relevant to antigen-specific immune responses.

Antigen Presentation Assays: The peptide serves as a critical tool for evaluating antigen presentation pathways in vitro. By pulsing antigen-presenting cells (APCs) with MART-1(24-33(34)), investigators can assess the efficiency and fidelity of peptide loading onto major histocompatibility complex (MHC) class I molecules. These assays provide insights into the mechanisms of peptide processing, MHC binding affinity, and the stability of peptide-MHC complexes, which are foundational for understanding immune surveillance and the design of immunotherapeutic strategies.

T Cell Activation Studies: MART-1(24-33(34)) is frequently used to stimulate antigen-specific CD8+ T cells in functional assays. In these experiments, the peptide enables quantitative and qualitative assessment of T cell activation, cytokine release, proliferation, and cytotoxic activity. Such studies are essential for characterizing T cell clones, optimizing expansion protocols, and evaluating the functional competence of immune effectors in response to defined tumor antigens.

Peptide-Based Vaccine Research: The defined sequence and immunogenic nature of MART-1(24-33(34)) make it a preferred candidate in peptide vaccine development and preclinical immunization models. Researchers employ the peptide to investigate the immunogenicity, safety, and efficacy of peptide-based formulations, as well as to explore adjuvant effects and delivery systems that enhance antigen-specific responses. These studies contribute to the rational design of next-generation cancer vaccines and immunomodulatory interventions.

Flow Cytometry and Tetramer Staining: The peptide is integral to the preparation of MHC-peptide tetramers for flow cytometric analysis of antigen-specific T cells. By incorporating MART-1(24-33(34)) into tetramer complexes, scientists can accurately quantify and characterize the frequency, phenotype, and functional state of T cells recognizing this epitope in complex biological samples. This application supports immune monitoring, biomarker discovery, and the evaluation of cellular immunity in experimental and translational research settings.

1. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

2. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

3. P-selectin and Complement’s Role in a Neonatal Model of Germinal Matrix Hemorrhage-Induced Secondary Injury

4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

5. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function